The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
BIOVENTUS COM CL A 09075A108   37,631,626 13,021,324 SH   SOLE   13,021,324 0 0
EYEPOINT PHARMACEUTICALS INC COM NEW 30233G209   36,461,013 4,190,921 SH   SOLE   4,190,921 0 0
MEDICINOVA INC COM NEW 58468P206   2,543,664 1,105,941 SH   SOLE   1,105,941 0 0
REVANCE THERAPEUTICS INC COM 761330109   11,568,821 457,085 SH   SOLE   457,085 0 0
TELA BIO, INC. COM 872381108   41,641,482 4,110,709 SH   SOLE   4,110,709 0 0
VENUS CONCEPT, INC. COM 92332W105   2,287,299 1,089,190 SH   SOLE   1,089,190 0 0